GSK’s Malaria Vaccine Phase 3 Study Containing Agenus’ QS-21 Published in The Lancet
Final study results show significant reduction in malaria cases
EMA currently reviewing the regulatory application
LEXINGTON, Mass.-- Agenus Inc. (AGEN), an immunology company developing innovative treatments for cancers and other diseases, announced today that final results from a large-scale Phase 3 study of GlaxoSmithKline’s (GSK) malaria vaccine candidate, RTS,S, were published in The Lancet. The study demonstrated a statistically significant reduction against malaria in children who received RTS,S followed by a booster shot of the vaccine at 18 months. RTS,S incorporates QS-21 Stimulon®, Agenus’ adjuvant designed to increase the immune response to antigens in vaccines.
- Category: Biotech
- Published: 24 April 2015
- Written by Editor